ArticleOncotarget2016
ROS1 copy number alterations are frequent in non-small cell lung cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Assessment of ROS1 Gene Rearrangement in Non-Small Cell Lung Cancer: Concordance Between ROS1 SP384 Immunohistochemistry and ROS1 FISH Assay in a Single Center in Türkiye.Turk patoloji dergisi · 2026Article
- Lung adenocarcinoma patients withHeliyon · 2024Article
- Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Routine Clinically Detected IncreasedJTO clinical and research reports · 2023Article
- Comprehensive NGS profiling to enable detection ofFrontiers in oncology · 2023Article
- Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas.Translational lung cancer research · 2022Article
- The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.Current oncology (Toronto, Ont.) · 2022Article
- Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2022Observational
- Immunohistochemical and Electron Microscopy Evolution in the Diagnosis of Lung Cancer in Iraq.Archives of Razi Institute · 2022Article
- Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing.Experimental and therapeutic medicine · 2021Article
- Clinical characteristics of patients withTranslational cancer research · 2020Article
- Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.Journal of translational medicine · 2019Article
- Article
- Clinicopathological characteristics ofOncotarget · 2017Article
- A consensus statement on the gender perspective in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Review
- Recent advances in the management of non-small cell lung cancer.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the correlation between FISH and IHC assays, and to investigate clinical implications of ROS1 copy number alterations (CNAs).
methodsA total of 314 NSCLC patients were screened using ROS1 FISH break-apart probes. Of these, 47 surgical tumors were included in TMAs to analyze ROS1 heterogeneity assessed either by FISH and IHC, and chromosome 6 aneusomy. To characterize ROS1 partners, probes for CD74, EZR, SLC34A2 and SDC3 genes were developed. ROS1 positive FISH cases were screened also by IHC.
resultsFive patients were ROS1 positive (1.8%). We identified two known fusion partners in three patients: CD74 and SLC34A2. Four out of five ROS1 rearranged patients were female, never smokers and with adenocarcinoma histology. Rearranged cases were also positive by IHC as well. According to ROS1 CNAs, we found a prevalence of 37.8% gains/amplifications and 25.1% deletions.
conclusionsThis study point out the high prevalence of ROS1 CNAs in a large series of NSCLC. ROS1 gains, amplifications and deletions, most of them due to chromosome 6 polysomy or monosomy, were heterogeneous within a tumor and had no impact on overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.